BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 34777388)

  • 1. The Impact of Immune Microenvironment on the Prognosis of Pancreatic Ductal Adenocarcinoma Based on Multi-Omics Analysis.
    Yang B; Zhou M; Wu Y; Ma Y; Tan Q; Yuan W; Ma J
    Front Immunol; 2021; 12():769047. PubMed ID: 34777388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
    Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
    Front Immunol; 2021; 12():690056. PubMed ID: 34335594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification, Validation, and Utilization of Immune Cells in Pancreatic Ductal Adenocarcinoma Based on Marker Genes.
    de Koning W; Latifi D; Li Y; van Eijck CHJ; Stubbs AP; Mustafa DAM
    Front Immunol; 2021; 12():649061. PubMed ID: 33986743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel lactylation-related signature to predict prognosis for pancreatic adenocarcinoma.
    Peng T; Sun F; Yang JC; Cai MH; Huai MX; Pan JX; Zhang FY; Xu LM
    World J Gastroenterol; 2024 May; 30(19):2575-2602. PubMed ID: 38817665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma.
    Chen D; Huang H; Zang L; Gao W; Zhu H; Yu X
    Front Immunol; 2021; 12():728062. PubMed ID: 34691034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
    Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H
    Front Immunol; 2021; 12():769425. PubMed ID: 34804059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas.
    Zhuang H; Wang S; Chen B; Zhang Z; Ma Z; Li Z; Liu C; Zhou Z; Gong Y; Huang S; Hou B; Chen Y; Zhang C
    Front Immunol; 2021; 12():790661. PubMed ID: 34925373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Immunological Biomarkers: Prognosis of Pancreatic Cancer Patients Reflected by the Immune System.
    van der Sijde F; Mustafa DAM; Vietsch EE; Katsikis PD; van Eijck CHJ
    Pancreas; 2021 Aug; 50(7):933-941. PubMed ID: 34643608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
    George B; Kudryashova O; Kravets A; Thalji S; Malarkannan S; Kurzrock R; Chernyavskaya E; Gusakova M; Kravchenko D; Tychinin D; Savin E; Alekseeva L; Butusova A; Bagaev A; Shin N; Brown JH; Sethi I; Wang D; Taylor B; McFall T; Kamgar M; Hall WA; Erickson B; Christians KK; Evans DB; Tsai S
    Gastroenterology; 2024 May; 166(5):859-871.e3. PubMed ID: 38280684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance and immune infiltration of microenvironment-related signatures in pancreatic cancer.
    Lu Q; Zhang Y; Chen X; Gu W; Ji X; Chen Z
    Medicine (Baltimore); 2021 Mar; 100(12):e24957. PubMed ID: 33761652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma.
    Luan H; Zhang C; Zhang T; He Y; Su Y; Zhou L
    Dis Markers; 2020; 2020():8825997. PubMed ID: 32934754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma.
    Kandimalla R; Tomihara H; Banwait JK; Yamamura K; Singh G; Baba H; Goel A
    Clin Cancer Res; 2020 Jul; 26(14):3641-3648. PubMed ID: 32234757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and validation of a novel immunological model to predict prognosis in pancreatic ductal adenocarcinoma.
    Liu J; He M
    Int Immunopharmacol; 2024 Jun; 134():112266. PubMed ID: 38761784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-related genes
    Zhang M; Zeng L; Peng Y; Fan B; Chen P; Liu J
    Future Oncol; 2021 Aug; 17(23):3061-3076. PubMed ID: 34156282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
    Hu Y; Chen Y
    Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification.
    Chen Y; Chen D; Wang Q; Xu Y; Huang X; Haglund F; Su H
    Front Immunol; 2021; 12():719105. PubMed ID: 35111149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Risk Model and Tumor Immune Environment Modulation of m5C-Related LncRNAs in Pancreatic Ductal Adenocarcinoma.
    Yuan H; Liu J; Zhao L; Wu P; Chen G; Chen Q; Shen P; Yang T; Fan S; Xiao B; Jiang K
    Front Immunol; 2021; 12():800268. PubMed ID: 34956238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using ESTIMATE algorithm to establish an 8-mRNA signature prognosis prediction system and identify immunocyte infiltration-related genes in Pancreatic adenocarcinoma.
    Meng Z; Ren D; Zhang K; Zhao J; Jin X; Wu H
    Aging (Albany NY); 2020 Mar; 12(6):5048-5070. PubMed ID: 32181755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.